Gemcitabine in non-small cell lung cancer (NSCLC)

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F00%3A00003719" target="_blank" >RIV/00216208:11120/00:00003719 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1023/a:1006327729228" target="_blank" >http://dx.doi.org/10.1023/a:1006327729228</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1023/a:1006327729228" target="_blank" >10.1023/a:1006327729228</a>

Result language
angličtina
Original language name
Gemcitabine in non-small cell lung cancer (NSCLC)
Original language description
The role of chemotherapy in the treatment of non-small cell lung cancer (NSCLC) has increased greatly in the past few years. While cytotoxic drugs are currently used both as single agents and in combination for palliation in locally advanced and metastatic disease, they have also been incorporated into multi-modality treatment strategies of Stage I to Stage III NSCLC. One of the main reasons for the increased acceptance of chemotherapy is the development of new substances. Among the most promising of these new drugs is the antimetabolite gemcitabine. Several single-arm gemcitabine Phase II studies involving more than 400 patients show validated response rates in more than 20% of the patients. These positive results have also been confirmed in randomized Phase II studies. Gemcitabine's unique mechanism of action, its lack of overlapping toxicity with other agents, and its favorable toxicity profile also define it as an ideal candidate for combination therapy. The activity seen with sing
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—

Publication year
2000
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)